BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
2.980
-0.080 (-2.61%)
At close: May 15, 2026, 4:00 PM EDT
3.060
+0.080 (2.68%)
After-hours: May 15, 2026, 5:52 PM EDT
BioLineRx Revenue
In the year 2025, BioLineRx had annual revenue of $1.18M, down -95.92%. BioLineRx had revenue of $194.00K in the quarter ending December 31, 2025, a decrease of -98.35%.
Revenue (ttm)
$1.18M
Revenue Growth
-95.92%
P/S Ratio
10.61
Revenue / Employee
$49,167
Employees
24
Market Cap
12.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18M | -27.76M | -95.92% |
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
| Dec 31, 2023 | 4.80M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBLRX News
- 19 days ago - BioLineRx, Hemispherian: First patient dosed in Phase 1/2a Study of GLIX1 - TheFly
- 19 days ago - BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - PRNewsWire
- 5 weeks ago - BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial - GuruFocus
- 5 weeks ago - BioLineRx, Hemispherian initiate clinical trial of GLIX1 - TheFly
- 5 weeks ago - Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma - Business Wire
- 7 weeks ago - BioLineRx initiates Phase 1/2a study of GLIX1 - TheFly
- 7 weeks ago - BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - PRNewsWire
- 7 weeks ago - BioLineRx Earnings Call Transcript: Q4 2025 - Transcripts